Caribou Biosciences (NASDAQ:CRBU) Cut to Hold at Brookline Capital Markets

Brookline Capital Markets lowered shares of Caribou Biosciences (NASDAQ:CRBU) from a buy rating to a hold rating in a research report report published on Wednesday, MarketBeat reports.

A number of other research firms have also commented on CRBU. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Friday, July 17th. Wall Street Zen lowered Caribou Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Leerink Partners reaffirmed a “market perform” rating and issued a $1.00 price target (down from $4.00) on shares of Caribou Biosciences in a report on Wednesday. Royal Bank Of Canada downgraded shares of Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 price target on the stock. in a research report on Wednesday. Finally, Bank of America decreased their price objective on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Caribou Biosciences presently has an average rating of “Hold” and a consensus target price of $5.50.

Caribou Biosciences Stock Down 4.4%

NASDAQ:CRBU opened at $0.46 on Wednesday. The firm has a market cap of $49.34 million, a PE ratio of -0.43 and a beta of 2.31. Caribou Biosciences has a 12 month low of $0.44 and a 12 month high of $3.54. The company’s 50-day moving average price is $1.41 and its two-hundred day moving average price is $1.73.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.08. The company had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.28 million. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. On average, research analysts expect that Caribou Biosciences will post -1.17 EPS for the current fiscal year.

Institutional Trading of Caribou Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in CRBU. BlackRock Inc. acquired a new position in shares of Caribou Biosciences in the 2nd quarter valued at $13,756,000. Renaissance Technologies LLC increased its holdings in Caribou Biosciences by 58.0% in the first quarter. Renaissance Technologies LLC now owns 2,590,497 shares of the company’s stock valued at $4,922,000 after purchasing an additional 950,640 shares during the last quarter. Bank of America Corp DE bought a new stake in Caribou Biosciences in the second quarter valued at about $2,483,000. GSA Capital Partners LLP acquired a new position in Caribou Biosciences in the second quarter valued at about $816,000. Finally, Green Alpha Advisors LLC bought a new position in Caribou Biosciences during the second quarter worth about $641,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences News Roundup

Here are the key news stories impacting Caribou Biosciences this week:

• Positive Sentiment: Leerink Partners set a $1.00 price target, substantially above the recent trading level, suggesting potential upside if Caribou’s clinical and business outlook improves. However, the firm simultaneously downgraded the stock to “Market Perform.” Leerink Partners Downgrades Caribou Biosciences to Market Perform
• Neutral Sentiment: HC Wainwright downgraded Caribou from “Buy” to “Neutral” and issued forecasts for continued losses through 2027: $(0.11) EPS in the first quarter, $(0.08) in the second, $(0.07) in the third and $(0.05) in the fourth. The estimates imply gradual improvement but no near-term profitability. HC Wainwright Downgrades Caribou Biosciences to Neutral
• Neutral Sentiment: Reported short interest totaled zero shares as of October 9, producing a zero-day days-to-cover ratio. This indicates no measurable short-position overhang in the reported data, although the figure may reflect a reporting anomaly rather than a meaningful change in investor positioning.
• Negative Sentiment: Brookline Capital Markets also downgraded Caribou to “Hold,” adding to the recent wave of more cautious analyst opinions. Brookline Capital Markets Downgrades Caribou Biosciences to Hold
• Negative Sentiment: A MedCity News report described Caribou’s off-the-shelf cell-therapy effort as reaching the “end of the road,” raising concerns about the company’s pipeline, future catalysts and ability to create shareholder value. Caribou Bio’s Journey With Off-the-Shelf Cell Therapy Reaches the End of the Road

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.